{
    "data": [
        {
            "id": "6903d048ecb8a7000145cc32",
            "title": "Strategy Stock Rallies After Mixed Q3, 26% Bitcoin Yield YTD",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Strategy Inc. </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MSTR\" target=\"_blank\">MSTR</a>) released its third-quarter earnings report after Thursday's closing bell. Here's <a href=\"https://www.benzinga.com/pressreleases/25/10/b48544531/strategy-announces-third-quarter-2025-financial-results-net-income-of-2-8-billion-and-diluted-eps-\" target=\"_blank\">what to know: </a></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>MSTR stock is up.<a href=\"https://www.benzinga.com/quote/MSTR\" target=\"_blank\"> See the real-time price action here.</a></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>The Details:</strong> Strategy reported quarterly earnings of $8.42 per share, which missed the analyst consensus estimate of $10.57.</p><!--/$--><!--$--><p class=\"block core-block\">Quarterly revenue came in at $128.69 million, which beat the Street estimate of $118.43 million.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">Strategy reported the following <strong>Bitcoin</strong> (CRYPTO: <a class=\"ticker\" href=\"https://www.benzinga.com/quote/btc/usd\" target=\"_blank\">BTC</a>) highlights as of Oct. 26, 2025:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>640,808 Bitcoin holdings at a total cost of $47.44 billion, or $74,032 per Bitcoin</li>\n<li>26% Bitcoin yield achieved in 2025 to date</li>\n<li>$12.9 billion gain achieved in 2025 to date</li>\n</ul><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\">“In the third quarter and into October, Strategy continued to strengthen its position as the world’s leading Bitcoin Treasury Company. We increased our bitcoin holdings to 640,808 bitcoin and have raised $20 billion year-to-date through our robust capital markets platform,” said <strong>Phong Le</strong>, CEO.</p><!--/$--><!--$--><p class=\"block core-block\">“With this momentum, we are reaffirming our full year targets of $20 billion BTC $ Gain and 30% BTC Yield,” Le added. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Outlook: </strong>Strategy affirmed its fiscal 2025 GAAP EPS guidance of $80, versus the $40.78 analyst estimate.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>MSTR Stock Price:</strong> According to data from<a href=\"https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw\" target=\"_blank\"> Benzinga Pro</a>, Strategy stock was up 2.33% at $260.51 in Thursday's extended trading. </p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48545856\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48535521/googles-q3-sends-stock-to-new-highs-analysts-say-ai-momentum-is-nanobananas\" target=\"_blank\"><strong>Google’s Q3 Sends Stock To New Highs, Analysts Say ‘AI Momentum Is Nanobananas’</strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/MicroStrategy-Stock-Jump.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48545856/strategy-stock-rallies-after-mixed-q3-26-bitcoin-yield-ytd",
            "pub_date": "2025-10-31 04:53:32",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903d140ecb8a7000145ccb7",
            "title": "Apple Stock Hits All-Time High Following Q4 Earnings Beat, Active Installed Base Reaches Record Levels Across All Products",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Apple Inc </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AAPL\" target=\"_blank\">AAPL</a>) reported financial results for the fourth quarter of fiscal 2025 Thursday after the close. Here’s a rundown of the <a href=\"https://www.benzinga.com/pressreleases/25/10/b48544888/apple-reports-fourth-quarter-results\" target=\"_blank\">iPhone maker’s report</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>AAPL is reaching significant price levels. <a href=\"https://www.benzinga.com/quote/AAPL\" rel=\"noreferrer noopener\" target=\"_blank\">Get the inside scoop here.</a></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Q4 Highlights:</strong> Apple reported fiscal fourth-quarter revenue of $102.47 billion, beating analyst <a href=\"https://www.benzinga.com/quote/AAPL/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">estimates</a> of $102.17 billion. The tech giant reported fourth-quarter earnings of $1.85 per share, beating analyst estimates of $1.76 per share.</p><!--/$--><!--$--><p class=\"block core-block\">Apple has a strong history of topping analyst estimates. With Thursday’s better-than-expected results, the company has now beat expectations on the top and bottom lines in 11 straight quarters, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><p class=\"block core-block\">Total revenue was up 8% year-over-year, and earnings per share climbed 13% year-over-year. Americas sales totaled $44.19 billion in the quarter, Europe sales came in at $28.7 billion, Greater China sales were approximately $14.49 billion, Japan sales totaled $6.64 billion and the rest of Asia Pacific sales were $8.44 billion.</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\">Product revenue came in at $73.72 billion, up from $69.96 billion year-over-year. Services revenue totaled $28.75 billion, up from $24.97 billion year-over-year. Here’s a breakdown of product sales by category.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>iPhone:</strong> $49.02 billion, versus $46.22 billion last year</li>\n<li><strong>Mac:</strong> $8.73 billion, versus $7.74 billion last year</li>\n<li><strong>iPad:</strong> $6.952 billion, versus $6.950 billion last year</li>\n<li><strong>Wearables, Home and Accessories</strong>: $9.01 billion, versus $9.04 billion last year</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Apple noted that its active installed base of devices once again reached new all-time highs across all product categories and geographic segments. The company attributed the growth to “very high levels” of customer satisfaction and loyalty.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">“Today, Apple is very proud to report a September quarter revenue record of $102.5 billion, including a September quarter revenue record for iPhone and an all-time revenue record for Services,” said <strong>Tim Cook</strong>, CEO of Apple.</p><!--/$--><!--$--><p class=\"block core-block\">“In September, we were thrilled to launch our best iPhone lineup ever, including iPhone 17, iPhone 17 Pro and Pro Max, and iPhone Air. In addition, we launched the fantastic AirPods Pro 3 and the all-new Apple Watch lineup. When combined with the recently announced MacBook Pro and iPad Pro with the powerhouse M5 chip, we are excited to be sharing our most extraordinary lineup of products as we head into the holiday season.”</p><!--/$--><!--$--><p class=\"block core-block\">Apple ended the quarter with $35.93 billion in cash and cash equivalents. The company's board declared a quarterly cash dividend of 26 cents per share, payable on Nov. 13 to shareholders of record as of Nov. 10.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Apple executives will further discuss the quarter on an <a href=\"https://www.youtube.com/live/j2se-TYG3hw\" target=\"_blank\">earnings call</a> scheduled for 5 p.m. ET. The company tends to provide commentary on how it generally expects its different product lines to perform over the coming months.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>AAPL Price Action:</strong> <a href=\"http://benzinga.com/quote/aapl\" rel=\"noreferrer noopener\" target=\"_blank\">Apple shares</a> are volatile following the earnings release. The stock initially fell, but was up 4.27% in after-hours, trading at $283 at the time of publication on Thursday, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48545962\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/news/politics/25/10/48467333/nancy-pelosi-ditches-apple-stock-right-before-q4-earnings-but-theres-a-catch\" target=\"_blank\"><strong>Nancy Pelosi Ditches Apple Stock Right Before Q4 Earnings – But There’s A Catch</strong></a></li>\n<li><a href=\"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48439252/apple-iphone-17-foldable-will-be-the-real-game-changer-analyst\" target=\"_blank\"><strong>Apple’s Upcoming Foldable iPhone Model Will Drive Major Upside: Analyst</strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image created using artificial intelligence via MidJourney.</em></p><!--/$--><!--$--><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/apple-mid3.png",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48545962/apple-stock-hits-all-time-high-following-q4-earnings-beat-active-installed-base-reaches-record-levels-across-all-products",
            "pub_date": "2025-10-31 04:57:39",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903c454ecb8a7000145c077",
            "title": "Behind the Scenes of Docusign&#39;s Latest Options Trends",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Deep-pocketed investors have adopted a bullish approach towards Docusign (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/DOCU\" target=\"_blank\">DOCU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DOCU usually suggests something big is about to happen.</p><!--/$--><!--$--><p class=\"block core-block\">We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Docusign. This level of activity is out of the ordinary.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The general mood among these heavyweight investors is divided, with 62% leaning bullish and 25% bearish. Among these notable options, 2 are puts, totaling $63,713, and 6 are calls, amounting to $264,490.</p><!--/$--><!--$--><h3 class=\"block core-block\">Predicted Price Range</h3><!--/$--><!--$--><p class=\"block core-block\">Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $85.0 for Docusign over the recent three months. </p><!--/$--><!--$--><div class=\"sc-ewfYpr ctXQJP\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Volume &amp; Open Interest Trends</h3><!--/$--><!--$--><p class=\"block core-block\">In today's trading context, the average open interest for options of Docusign stands at 725.25, with a total volume reaching 1,006.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Docusign, situated within the strike price corridor from $70.0 to $85.0, throughout the last 30 days.</p><!--/$--><!--$--><h3 class=\"block core-block\">Docusign Option Volume And Open Interest Over Last 30 Days</h3><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUwMCIgaGVpZ2h0PSI4MDAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyIgdmVyc2lvbj0iMS4xIi8+\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 1500px, (min-width: 800px) 1500px\" src=\"https://www.benzinga.com/files/images/story/2025/1761854549_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761854549_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 1x, https://www.benzinga.com/files/images/story/2025/1761854549_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Largest Options Trades Observed:</h3><!--/$--><!--$--><!--/$--><!--$--><h3 class=\"block core-block\">About Docusign</h3><!--/$--><!--$--><p class=\"block core-block\">Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Having examined the options trading patterns of Docusign, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p><!--/$--><!--$--><h3 class=\"block core-block\">Docusign's Current Market Status</h3><!--/$--><!--$--><ul class=\"block core-block\">\n<li>Trading volume stands at 3,876,848, with DOCU's price up by 3.83%, positioned at $71.62.</li>\n<li>RSI indicators show the stock to be may be approaching overbought.</li>\n<li>Earnings announcement expected in 35 days.</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">What The Experts Say On Docusign</h3><!--/$--><!--$--><p class=\"block core-block\">A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $124.0.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Turn $1000 into $1270 in just 20 days?</strong></p><!--/$--><!--$--><p class=\"block core-block\">20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href=\"https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Click here for access</strong></a>.\n* In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $124. </p><!--/$--><!--$--><p class=\"block core-block\">Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Docusign options trades with real-time alerts from <a href=\"https://www.benzinga.com/pro/\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/options/25/10/48543200/behind-the-scenes-of-docusigns-latest-options-trends",
            "pub_date": "2025-10-31 04:02:32",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903c4d8ecb8a7000145c132",
            "title": "Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here&#39;s How ETFs Stand To Gain",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/etfs\" target=\"_blank\">Healthcare ETFs</a> are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As <strong>Eli Lilly And Co</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">LLY</a>), <strong>Novo Nordisk A/S</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVO\" target=\"_blank\">NVO</a>), and <strong>Pfizer Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PFE\" target=\"_blank\">PFE</a>) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far less calorie-dense ways to play the trend.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><em>Elli Lily stock is up almost 5% on Thursday. <a href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">Track its prices, live</a>.</em></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The <strong>Health Care Select Sector SPDR Fund</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/XLV\" target=\"_blank\">XLV</a>) is one of the largest and most liquid U.S. healthcare ETFs, with Eli Lilly as its top holding. Lilly alone constitutes over 12% of the fund, which also includes heavyweights like <strong>Johnson &amp; Johnson </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/JNJ\" target=\"_blank\">JNJ</a>), <strong>AbbVie Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ABBV\" target=\"_blank\">ABBV</a>) and <strong>Merck &amp; Co Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MRK\" target=\"_blank\">MRK</a>), making XLV a go-to for investors seeking broad yet concentrated exposure to the pharma surge.</p><!--/$--><!--$--><p class=\"block core-block\">The <strong>iShares U.S. Pharmaceuticals ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/IHE\" target=\"_blank\">IHE</a>) offers an even more targeted play, with roughly 20 of America's biggest drugmakers, including Lilly and Pfizer. The fund has gained traction this week as investors digest Lilly's blowout earnings and Novo's <a href=\"https://www.benzinga.com/m-a/25/10/48533502/pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless\" target=\"_blank\">audacious takeover bid for Metsera</a>. On Thursday, the fund was up almost 2%. </p><!--/$--><!--$--><p class=\"block core-block\">The <strong>VanEck Pharmaceutical ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PPH\" target=\"_blank\">PPH</a>) adds a global flavor to the mix, combining U.S. and European pharma names like Novo Nordisk alongside Lilly and Pfizer to give it a front-row seat to the obesity drug arms race.</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\">For investors who prefer the theme-first approach, the <strong>Roundhill GLP-1 &amp; Weight Loss ETF </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/OZEM\" target=\"_blank\">OZEM</a>) has emerged as a pure-play bet on the anti-obesity revolution. The fund focuses exclusively on companies leading the charge of this megatrend in weight loss and diabetes treatment, from established GLP-1 producers to emerging biotech developers.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Eli Lilly Leads, Rivals Fight </h2><!--/$--><!--$--><p class=\"block core-block\">Setting the tone for the sector were third-quarter results from Eli Lilly, whose adjusted earnings of $7.02 per share topped estimates and raised its full-year profit forecast to as high as $23.70. </p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">But across the Atlantic, Novo Nordisk is making headlines of its own, launching a $6.5 billion counterbid for U.S. biotech Metsera, edging out Pfizer’s earlier deal. Metsera is developing a few experimental weight-loss treatments, including a shot that can be taken less frequently than Novo Nordisk's Wegov, making the deal attractive to the giant.</p><!--/$--><!--$--><p class=\"block core-block\">Pfizer, which is still regaining its footing after the pandemic vaccine windfall faded, called Novo’s move “reckless” and anticompetitive, but the fight underscores how high the stakes have become in the GLP-1 gold rush.</p><!--/$--><!--$--><p class=\"block core-block\">With Lilly tightening its lead, Novo flexing its balance sheet, and Pfizer trying to claw back relevance, the obesity-drug race is reshaping the global pharma landscape-and ETFs are emerging as the easiest way to stay invested in the frenzy. </p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48543376\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/etfs/sector-etfs/25/10/48535168/nvidias-5-trillion-milestone-turns-these-ai-etfs-into-hot-trades\" target=\"_blank\">Nvidia’s $5 Trillion Milestone Turns These AI ETFs Into Hot Trades</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by shisu_ka via Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg",
            "link": "https://www.benzinga.com/etfs/sector-etfs/25/10/48543376/eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash-heres-how-etfs-stand-to-gain",
            "pub_date": "2025-10-31 04:04:44",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903ce7becb8a7000145cacb",
            "title": "Here&#39;s How Much $1000 Invested In RBC Bearings 10 Years Ago Would Be Worth Today",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">RBC Bearings (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/RBC\" target=\"_blank\">RBC</a>) has outperformed the market over the past 10 years by 6.92% on an annualized basis producing an average annual return of 19.37%. Currently, RBC Bearings has a market capitalization of $12.83 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $1000 In RBC:</strong> If an investor had bought $1000 of RBC stock 10 years ago, it would be worth <strong>$5,849.88</strong> today based on a price of $406.45 for RBC at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">RBC Bearings's Performance Over Last 10 Years</h3><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUwMCIgaGVpZ2h0PSI4MDAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyIgdmVyc2lvbj0iMS4xIi8+\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 1500px, (min-width: 800px) 1500px\" src=\"https://www.benzinga.com/files/images/story/2025/1761857148_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761857148_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 1x, https://www.benzinga.com/files/images/story/2025/1761857148_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-ewfYpr ctXQJP\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/25/10/48545547/heres-how-much-1000-invested-in-rbc-bearings-10-years-ago-would-be-worth-today",
            "pub_date": "2025-10-31 04:45:51",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}